After having a successful IPO less than a year ago, this biotech innovator had notable insider transactions to close out 2025.
The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback